MedPath

ReActiv8 Stimulation Therapy vs Optimal Medical Management: A Randomized Evaluation

Not Applicable
Active, not recruiting
Conditions
Chronic Low-back Pain
Registration Number
NCT04803214
Lead Sponsor
Mainstay Medical
Brief Summary

This study is a prospective, randomized study comparing ReActiv8 Therapy to Optimal Medical Management (OMM).

Detailed Description

This study is a prospective, randomized study comparing ReActiv8 Therapy to Optimal Medical Management (OMM), where OMM means the patient is managed according to available guideline-directed treatments (e.g., medication, physical therapy, injections) individualized to meet the patient needs. All patients who satisfy the enrollment criteria are randomized (1:1) to receive either ReActiv8 (Treatment group) or OMM (Control group).

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
203
Inclusion Criteria
  1. Age ≥21 years
  2. Evidence of lumbar multifidus muscle dysfunction
  3. Intractable Chronic Low Back Pain that has persisted >6 months resulting in pain most of the days in the past 12 months
  4. Failed therapy including pain medications and physical therapy
  5. Not a candidate for spine surgery
  6. Low Back Pain NRS of ≥6 and ≤9
  7. Oswestry Disability Index score ≥30 and ≤60
  8. Willing and capable of giving Informed Consent
  9. Able to comply with this protocol
  10. On Optimal Medical Management per the Investigator
Exclusion Criteria
  1. Contraindicated for the ReActiv8 System
  2. BMI > 35
  3. Any surgical correction procedure for scoliosis at any time, or a current clinical diagnosis of moderate to severe scoliosis
  4. An independent MRI assessment identifying a pathology that is likely the cause of the CLBP and is amenable to surgery
  5. Leg pain described as being worse than back pain, or radiculopathy (neuropathic pain) below the knee
  6. Any condition unrelated to CLBP which, in the opinion of the Investigator, could limit physical movement or compliance with the protocol, or interfere with the assessment of efficacy
  7. Surgical and other procedure exclusions
  8. Psycho-social exclusions
  9. Protocol compliance exclusions
  10. General exclusions

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Change in Oswestry Disability Index (ODI)1 year

Comparison of 1-year change from baseline in ODI between Treatment and Control with MMRM for missing data.

ODI is measured on a scale of 0 to 100 where a lower score is a better outcome.

Secondary Outcome Measures
NameTimeMethod
Change in Low Back Pain Numerical Rating Scale (LBP NRS)1 year

Comparison of 1-year change from baseline in LBP NRS between Treatment and Control with MMRM for missing data.

NRS is measured on a scale of 0 to 10 where a higher score is a better outcome.

Change in EQ-5D1 year

Comparison of 1-year change from baseline in EQ-5D between Treatment and Control with MMRM for missing data.

EQ-5D is measured on a scale of -0.5 to 1.0 where a higher score is a better outcome.

Trial Locations

Locations (28)

SoCal Sport and Spine

🇺🇸

Newport Beach, California, United States

Barrow Brain & Spine

🇺🇸

Phoenix, Arizona, United States

University of Arkansas for Medical Sciences

🇺🇸

Little Rock, Arkansas, United States

Pacific Research Institute

🇺🇸

Santa Rosa, California, United States

University of Colorado

🇺🇸

Aurora, Colorado, United States

International Spine, Pain and Performance Center

🇺🇸

Washington, District of Columbia, United States

Cleveland Clinic Martin Health Tradition Hospital

🇺🇸

Port Saint Lucie, Florida, United States

Cantor Spine Center and Paley Orthopedic Spine Institute

🇺🇸

West Palm Beach, Florida, United States

Augusta Orthopedic & Sports Medicine Specialists

🇺🇸

Augusta, Georgia, United States

Horizon Clinical Research

🇺🇸

Fayetteville, Georgia, United States

Scroll for more (18 remaining)
SoCal Sport and Spine
🇺🇸Newport Beach, California, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.